(Q34590281)

3 August 2017

1 reference

title

Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate (English)

1 reference

3 August 2017

1 reference

1 reference

1 reference

Joachim Stangier

1

1 reference

3 August 2017

1 January 2008

1 reference

Clinical Pharmacokinetics

3 August 2017

1 reference

3 August 2017

47

1 reference

3 August 2017

285-295

1 reference

3 August 2017

5

1 reference

https://scigraph.springernature.com/pub.10.2165/00003088-200847050-00001

3 August 2017

0 references

cites work

Warfarin and other coumarin derivatives: pharmacokinetics, pharmacodynamics, and drug interactions

1 reference

12 December 2020

Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

1 reference

12 December 2020

VKORC1: molecular target of coumarins

1 reference

12 December 2020

Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study

1 reference

12 December 2020

Antithrombotic and anticoagulant effects of the direct thrombin inhibitor dabigatran, and its oral prodrug, dabigatran etexilate, in a rabbit model of venous thrombosis

1 reference

12 December 2020

The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects

1 reference

12 December 2020

Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement

1 reference

12 December 2020

The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans

1 reference

12 December 2020

Hirudin as alternative anticoagulant--a historical review

1 reference

12 December 2020

Pharmacokinetics of ximelagatran and relationship to clinical response in acute deep vein thrombosis

1 reference

12 December 2020

The pharmacodynamics and pharmacokinetics of the oral direct thrombin inhibitor ximelagatran and its active metabolite melagatran: a mini-review

1 reference

12 December 2020

Three different patterns of calibrated automated thrombogram obtained with six different anticoagulants

1 reference

12 December 2020

A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial.

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of ximelagatran

1 reference

12 December 2020

Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies.

1 reference

12 December 2020

Effects of the direct thrombin inhibitor dabigatran on ex vivo coagulation time in orthopaedic surgery patients: a population model analysis

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects

1 reference

12 December 2020

Therapeutical potential of direct thrombin inhibitors for atherosclerotic vascular disease

1 reference

12 December 2020

Direct thrombin inhibitors

1 reference

12 December 2020

Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis

1 reference

12 December 2020

In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate

1 reference

12 December 2020

Management of venous thromboembolism: past, present, and future

1 reference

12 December 2020

Structure-based design of novel potent nonpeptide thrombin inhibitors

1 reference

12 December 2020

Synthetic inhibitors of thrombin and factor Xa: from bench to bedside

1 reference

12 December 2020

1 reference

12 December 2020

Population pharmacokinetic analysis of the new oral thrombin inhibitor dabigatran etexilate (BIBR 1048) in patients undergoing primary elective total hip replacement surgery.

1 reference

12 December 2020

Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I.

1 reference

12 December 2020

10.2165/00003088-200847050-00001

Identifiers

DOI

1 reference

PubMed ID

18399711

Dimensions Publication ID

3 August 2017

0 references

1 reference

PubMed ID

18399711